

## Declaration for Patent Application

Docket Number: 0609.5140000/SRL/PAC

As a below named inventor, I hereby declare that:

My residence, mailing address and citizenship are as stated below next to my name.

I believe I am an original, first and joint inventor of the subject matter that is claimed and for which a patent is sought on the invention entitled **Conformationally Constrained Parathyroid Hormone (PTH) Analogs With Lactam Bridges**, the specification of which is attached hereto unless the following box is checked:

☒ was filed as United States Application Number 10/542,704; which is the National Phase entry of International Application Number PCT/US2003/002155, I.A. Filed January 24, 2003; and amended on July 20, 2005.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or (f) or § 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or § 365(a) of any PCT international application, which designated at least one country other than the United States of America, listed below, and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Applications(s):

Priority  
Claimed

☐ Yes ☐ No

\_\_\_\_\_  
(Application No.)      (Country)      (Day/Month/Year  
Filed)

☐ Yes ☐ No


\_\_\_\_\_  
(Application No.)      (Country)      (Day/Month/Year  
Filed)


Send Correspondence to:


Customer No. 26111  
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.  
1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934

Direct Telephone Calls to: (202) 371-2600

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first Inventor:	Thomas J. GARDELLA
Signature of first Inventor:	 Date: 3-10-06
Residence:	Needham, Massachusetts
Citizenship:	US
Mailing Address:	1045 Greendale Avenue Needham, Massachusetts 02492

Full name of second Inventor:	Henry M. KRONENBERG
Signature of second Inventor:	 Date: 3-8-06
Residence:	Boston, Massachusetts
Citizenship:	US
Mailing Address:	50 Blossom Street Boston, Massachusetts 02114

Full name of third Inventor:	John T. POTTS
Signature of third Inventor:	 Date: 3-10-06
Residence:	Charlestown, Massachusetts
Citizenship:	US
Mailing Address:	Building 149, 13th Street Charlestown, Massachusetts 02129

501801\_1.DOC

## POWER OF ATTORNEY FROM ASSIGNEE

The General Hospital Corporation, a corporation of Massachusetts, having a principal place of business at 55 Fruit Street, Boston, Massachusetts 02114, is assignee of the entire right, title, and interest for the United States of America (as defined in 35 U.S.C. §100), by reason of an Assignment to the Assignee executed on 1) 3/10/06, 2) 3/8/06, and 3) 3/10/06, of an invention known as **Conformationally Constrained Parathyroid Hormone (PTH) Analogs With Lactam Bridges** (Attorney Docket No. 0609.5140000/SRL/PAC), that is disclosed and claimed in a patent application of the same title by the inventors 1) Thomas J. GARDELLA, 2) Henry M. KRONENBERG and 3) John T. POTTS (said application having Application Number 10/542,704, which is the U.S. national phase of International Application No. PCT/US2003/002155, I.A. Filing Date January 24, 2003).

For the purpose of PAIR, the **Customer Number** is **26111**.

The Assignee hereby appoints the patent practitioners associated with **CUSTOMER NUMBER 26111** to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith. The Assignee hereby grants said patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

Send correspondence to:

**CUSTOMER NUMBER 26111**  
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.  
1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
U.S.A.

Direct phone calls to 202-371-2600.

FOR: The General Hospital Corporation

SIGNATURE: 

BY: Laura Gold Ripin  
Licensing Manager

TITLE: \_\_\_\_\_

DATE: 3/20/06

**STATEMENT UNDER 37 CFR 3.73(b)**

0609.5140000/SRL/PAC

Applicant/Patent Owner: GARDELLA et al.

Application No./Patent No./Control No.: 10/542,704 (U.S. Nat'l Stage of PCT/US2003/002155) Filed/Issue Date: I.A. Filed January 24, 2003

Entitled: Conformationally Constrained Parathyroid Hormone (PTH) Analogs With Lactam Bridges

The General Hospital Corporation, a

corporation

(Name of Assignee)

(Type of Assignee: corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest  
(The extent (by percentage) of its ownership interest is \_\_\_\_\_ %)

in the patent application/patent identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 017370, Frame 0055, or a true copy of the original assignment is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

[Signature]  
\_\_\_\_\_  
Linda Gold Ripin  
Licensing Manager

Printed or Typed Name

3/20/06  
\_\_\_\_\_  
Date

Telephone Number

\_\_\_\_\_  
Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.